Lipocine Inc.

LPCN ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Assets
Cash & Equivalents $5.2M $6.2M $4.8M $3.1M $3.0M $19.2M $9.7M $8.1M
Accounts Receivable — — — — — — — —
Inventory — — — — — — — —
Total Current Assets $16.9M $22.3M $22.9M $34.1M $46.4M $25.3M $19.6M $20.8M
Property, Plant & Equipment $104.3K $165.1K $116.1K $131.6K $7.2K — $3.6K $19.0K
Goodwill — — — — — — — —
Intangible Assets (Excl. Goodwill) — — — — — — — —
Total Assets $17.0M $22.5M $23.0M $37.5M $52.5M $25.4M $19.7M $20.9M
Liabilities
Accounts Payable $971.8K $271.7K $1.4M $600.4K $1.3M $1.6M $1.2M $671.3K
Total Current Liabilities $2.5M $1.5M $2.6M $1.7M $5.6M $6.6M $5.0M $4.5M
Long-Term Debt — — — — $1.7M $2.3M $3.8M $6.9M
Total Liabilities $2.5M $1.5M $2.6M $1.9M $6.9M $10.0M $13.4M $11.4M
Stockholders' Equity
Retained Earnings $-209.4M $-199.8M $-199.8M $-183.4M $-172.7M $-172.0M $-151.1M $-138.1M
Total Stockholders' Equity $14.5M $21.0M $20.4M $35.6M $45.6M $15.3M $6.3M $9.4M
← Newer Page 1 of 2 Older →